There are currently 116 active clinical trials seeking participants for Multiple Sclerosis research studies. The states with the highest number of trials for Multiple Sclerosis participants are Florida, New York, California and Ohio.
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
NCT05964829
Recruiting
The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/19/2025
Locations: Cleveland State University, Cleveland, Ohio
Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Register for Updates
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
NCT03109288
Recruiting
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to. Objective: To see if signs of inflammation in CSF help predict a person s response to different drugs. Eligibility: People ages 18 and older who: * Are in protocol 09-I-003... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Register for Updates
Nomad P-KAFO Study
NCT05644522
Recruiting
The goal of this clinical trial is to evaluate the impact of using the Nomad powered KAFO in people who have had a musculoskeletal or neurological injury that has affected their ability to walk. The main questions it aims to answer are to quantify the effectiveness of the Nomad in improving mobility, balance, frequency of falls, and quality of life in individuals with lower-extremity impairments compared to their own brace, over three months of daily home and community use. Participants will:... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/03/2025
Locations: Shirley Ryan AbilityLab, Chicago, Illinois
Conditions: Cerebrovascular Accident, Post-polio Syndrome, Spinal Cord Injuries, Multiple Sclerosis, Muscular Dystrophy, Paralysis
Register for Updates
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113
Recruiting
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/03/2025
Locations: UCSF, San Francisco, California +11 locations
Conditions: Multiple Sclerosis
Register for Updates
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/02/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +37 locations
Conditions: Multiple Sclerosis, Myasthenia Gravis
Register for Updates
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
NCT06433765
Recruiting
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
Gender:
FEMALE
Ages:
Between 15 years and 50 years
Trial Updated:
03/31/2025
Locations: BRIUMVI® Pregnancy Registry Virtual Research Coordination Center, Wilmington, North Carolina
Conditions: Multiple Sclerosis
Register for Updates
Smoldering Inflammation in MS
NCT06591429
Recruiting
The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal inflammation persist?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2025
Locations: Barnes Jewish Center for Clinical Imaging Research, St. Louis, Missouri
Conditions: Multiple Sclerosis
Register for Updates
Pathological Basis of MRI Signal Changes in Multiple Sclerosis
NCT02659956
Recruiting
Background: Multiple sclerosis (MS) is a disease that damages the central nervous system (brain and spinal cord). This leads to increased physical disability over time. The disease is lifelong once it begins. Researchers want to learn more about MS s stages and follow them until a person s death. Objective: To understand how the physical and clinical signs of MS relate to its changes over time. Eligibility: Adults age 18 or older with MS or a disease of the brain and spinal cord that may ac... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/28/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Register for Updates
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
NCT05170126
Recruiting
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
Gender:
FEMALE
Ages:
All
Trial Updated:
03/28/2025
Locations: Evidera, Bethesda, Maryland +2 locations
Conditions: Multiple Sclerosis
Register for Updates
Non-invasive BCI-controlled Assistive Devices
NCT05183152
Recruiting
Injuries affecting the central nervous system may disrupt the cortical pathways to muscles causing loss of motor control. Nevertheless, the brain still exhibits sensorimotor rhythms (SMRs) during movement intents or motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. Brain-computer interfaces (BCIs) can decode SMRs to control assistive devices and promote functional recovery. Despite rapid advancements in non-invasive BCI systems ba... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/28/2025
Locations: The University of Texas at Austin, Austin, Texas
Conditions: Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders, Multiple Sclerosis
Register for Updates
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
NCT00794352
Recruiting
Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This study will compare tests performed on both healthy volunteers and individuals who have signs or symptoms of immune-related damage to their CNS. This study will include two groups of subjects at least... Read More
Gender:
ALL
Ages:
Between 1 month and 99 years
Trial Updated:
03/28/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Central Nervous System Disease, Multiple Sclerosis
Register for Updates
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
NCT02784210
Recruiting
Background: Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways. Sometimes they light up from the outer edge and fill inward. This is called ring enhancement. Researchers think this type of lesion may not heal as well as others. Corticosteroids are the standard treatment to reduce symptoms of MS relapse. But there is no standard treatment for people with enhancing MS lesions without signs of M... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/26/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Register for Updates